Efficacy and tolerability of perampanel in patients with genetic generalized epilepsy (GGE): A retrospective, single-center study from the United Arab Emirates (UAE).

Abstract

•52.4% achieved seizure freedom at six months from baseline in our cohort of PWE from the UAE.•38.1% achieved ≥50% reduction in seizure frequency at six months from baseline.•90.5% remained on perampanel treatment beyond the six-month period.•33.3% maintained perampanel monotherapy beyond six months.•9.5% discontinued perampanel treatment due to treatment-induced adverse events.